NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Xencor, Inc. (XNCR) announced Tuesday it has entered into a technology license agreement with Bristol-Myers Squibb Co. (BMY) under which Bristol
Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement with Bristol-Myers Squibb Company under which Bristol Myers Squibb will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of a novel antibody … Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement with Bristol-Myers Squibb Company (NYSE:BMY) under which Bristol Myers Squibb will have non-exclusive access to Xencor’s Xtend™ Fc technology to
Herman
NEW YORK (Legal Newsline) - A New York man accuses former Rockefeller University professor Dr. Reginald Archibald, who was also a senior physician and Madison Square Boys Club board of directors member, of sexually abusing him as a child, according to documents filed April 1 in the New York Supreme Court.
The plaintiff, identified as JG, is one of dozens who have come forward in recent years. He says he started attending Madison Square in 1970 at approximately 10 years old and that he was repeatedly sexually assaulted by Dr. Archibald over the course of three years.
The physician is accused of forcing the plaintiff to remove his clothing, fondling his genitals and anal area without medical reason and taking photographs of JG in the nude without medical justification.
Search jobs 03-Feb-2021 Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
NEW YORK (BUSINESS WIRE) Bristol Myers Squibb (NYSE: BMY) and The Rockefeller University today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has been granted a global exclusive license to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.
Despite the increasing availability of the vaccines, there will continue to be patients who contract COVID-19 and will need treatment for their infection. This novel treatment is a combination of two mAbs directed at blocking the SARS-CoV-2 spike protein and neutralizing the virus. The mAbs have been engineered to be highly potent a
Bristol Myers Squibb (BMS) and The Rockefeller University announced on February 3, 2021, that they have entered into a definitive agreement under which BMS has been granted a global exclusive license to develop, manufacture, and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the